Emricasan

N/A

Report date: 2025/10/24 17:59:47
NMEFirst In Class

Base Information

Drug NameEmricasan
Drug Alias Name恩利卡桑Emricasanum恩利卡生IDN-6556VAY-785 +[7
ClassificationSmall molecules
Mechanisms of ActionCaspase inhibitorsApoptosis inhibitors
TargetsCaspase
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Decompensated Liver CirrhosisFibrosis +[19
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesGermany +[5
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesIdun Pharmaceuticals
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Active IndicationsN/A
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)Decompensated Liver CirrhosisFibrosis +[19

Other Information

ATC CodeN/A